SNF2H promotes hepatocellular carcinoma proliferation by activating the Wnt/β-catenin signaling pathway

Oncology Letters

Volumn 12, Issue 2, 2016, Pages 1329-1336

  Wang, Yanan ^a   Qin, Juanxiu ^a   Liu, Qian ^a   Hong, Xufen ^b   Li, Tianming ^a   Zhu, Yuanjun ^b   He, Lei ^a   Zheng, Bing ^a   Li, Min ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Proliferation; SNF2H; Wnt cateni

Indexed keywords

BETA CATENIN; PEPTIDES AND PROTEINS; SUCROSE NONFERMENTABLE CATALYTIC SUBUNIT SNF2; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MOLECULAR CLONING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WNT SIGNALING PATHWAY;

EID: 84977118021     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4681     Document Type: Article

References (33)

1. Ferlay J, Shin H, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Forner A, Hessheimer AJ, Isabel Real M and Bruix J: Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 60: 89-98, 2006.
3. Boyault S, Rickman DS, deReyniès A, Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti J, Franco D, et al: Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45: 42-52, 2007.
4. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480, 2006.
5. Takigawa Y and Brown AM: Wnt signaling in liver cancer. Curr Drug Targets 9: 1013-1024, 2008.
6. Polakis P: The many ways of Wnt in cancer. Curr Opin Genet Dev 17: 45-51, 2007.
7. Valenta T, Hausmann G and Basler K: The many faces and functions of β-catenin. EMBO J 31: 2714-2736, 2012.
8. Guigon CJ, Kim DW, Zhu X, Zhao L and Cheng SY: Tumor suppressor action of liganded thyroid hormone receptor beta by direct repression of beta-catenin gene expression. Endocrinology 151: 5528-5536, 2010.
9. Li Q, Dashwood WM, Zhong X, Al-Fageeh and Dashwood RH: Cloning of the rat beta-catenin gene (Ctnnb1) promoter and its functional analysis compared with the Catnb and CTNNB1 promoters. Genomics 83: 231-242, 2004.
10. Liu G, Jiang S, Wang C, et al: Zinc finger transcription factor 191, directly binding to β-catenin promoter, promotes cell proliferation of hepatocellular carcinoma. Hepatology 55: 1830-1839, 2012.
11. Liu Y, Ye X, Zhang JB, et al: PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation. Oncogene 34: 5524-5535, 2015.
12. Mohamed MA, Greif PA, Diamond J, Sharaf O, Maxwell P, Montironi R, Young RA and Hamilton PW: Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. BJU Int 99: 908-915, 2007.
13. Stopka T and Skoultchi AI: The ISWI ATPase Snf2h is required for early mouse development. Proc Natl Acad Sci USA 100: 14097-14102, 2003.
14. Reisman D, Glaros S and Thompson EA: The SWI/SNF complex and cancer. Oncogene 28: 1653-1668, 2009.
15. Jin Q, Mao X, Li B, Guan S, Yao F and Jin F: Overexpression of SMARCA5 correlates with cell proliferation and migration in breast cancer. Tumour Biol 36: 1895-1902, 2015.
16. Stopka T, Zakova D, Fuchs O, Kubrova O, Blafkova J, Jelinek J, Necas E and Zivny J: Chromatin remodeling gene SMARCA5 is dysregulated in primitive hematopoietic cells of acute leukemia. Leukemia 14: 1247-1252, 2000.
17. Gigek CO, Lisboa LC, Leal MF, Silva PN, Lima EM, Khayat AS, Assumpção PP, Burbano RR and Smith Mde A: SMARCA5 methylation and expression in gastric cancer. Cancer Invest 29: 162-166, 2011.
18. Cui J, Zhou X, Liu Y and Tang Z: Mutation and overexpression of the beta-catenin gene may play an important role in primary hepatocellular carcinoma among Chinese people. J Cancer Res Clin Oncol 127: 577-581, 2001.
19. Lai TY, Su CC, Kuo WW, Yeh YL, Kuo WH, Tsai FJ, Tsai CH, Weng YJ, Huang CY and Chen LM: β-catenin plays a key role in metastasis of human hepatocellular carcinoma. Oncol Rep 26: 415-422, 2011.
20. Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 6: 674-687, 2006.
21. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007.
22. Chen L, Chan TH, Yuan YF, et al: CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest 120: 1178-1191, 2010.
23. Liu Y, Zhang JB, Qin Y, et al: PROX1 promotes hepatocellular carcinoma metastasis by way of up-regulating hypoxia-inducible factor 1α expression and protein stability. Hepatology 58: 692-705, 2013.
24. Chuma M, Sakamoto M, Yasuda J, Fujii G, Nakanishi K, Tsuchiya A, Ohta T, Asaka M and Hirohashi S: Overexpression of cortactin is involved in motility and metastasis of hepatocellular carcinoma. J Hepatol 41: 629-636, 2004.
25. Lau SH, Sham JS, Xie D, Tzang CH, Tang D, Ma N, Hu L, Wang Y, Wen JM, Xiao G, Zhang WM, et al: Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 25: 1242-1250, 2006.
26. Sun CK, Ng KT, Sun BS, Ho JW, Lee TK, Ng I, Poon RT, Lo CM, Liu CL, Man K and Fan ST: The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence. Br J Cancer 97: 50-57, 2007.
27. Tung-Ping Poon R, Fan ST and Wong J: Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232: 10-24, 2000.
28. Yang W, Lu Y, Xu Y, Xu L, Zheng W, Wu Y, Li L and Shen P: Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs). J Biol Chem 287: 40140-40149, 2012.
29. Yang WL, Wei L, Huang WQ, Li R, Shen WY, Liu JY, Xu JM, Li B and Qin Y: Vigilin is overexpressed in hepatocellular carcinoma and is required for HCC cell proliferation and tumor growth. Oncol Rep 31: 2328-2334, 2014.
30. Jiang YF, Yang ZH and Hu JQ: Recurrence or metastasis of HCC: Predictors, early detection and experimental antiangiogenic therapy. World J Gastroenterol 6: 61-65, 2000.
31. Schmidt-Ott KM and Barasch J: WNT/beta-catenin signaling in nephron progenitors and their epithelial progeny. Kidney Int 74: 1004-1008, 2008.
32. Corona DF, Längst G, Clapier CR, Bonte EJ, Ferrari S, Tamkun JW and Becker PB: ISWI is an ATP-dependent nucleosome remodeling factor. Mol Cell 3: 239-245, 1999.
33. VargaWeisz PD and Becker PB: Chromatin-remodeling factors: Machines that regulate? Curr Opin Cell Biol 10: 346-353, 1998.